Mateon Therapeutics Inc (MATN)
0.2299 +0.1100 (+91.74%) 13:01 ET [OTC US]
NEWS & HEADLINES for Wed, Mar 25th, 2020Alerts Watch Help
Mateon Report Positive Results for Multiple COVID-19 Drug Candidates
GlobeNewswire - Wed Mar 25, 7:00AM CDT
Mateon Therapeutics, Inc. (OTCQB:MATN) ("Mateon") dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided an update on its rapid antiviral response program targeting...
MATN : 0.2290 (+90.99%)
Mateon Partners With Meridian IT To Fast Track Drug Manufacturing Using Artificial Intelligence For Coronaviruses, Including COVID-19
GlobeNewswire - Thu Mar 19, 7:00AM CDT
Mateon Therapeutics, Inc. (OTCQB:MATN) ("Mateon") announced today their expanded focus on artificial intelligence (AI) enabled EdgePoint projects by expanding their partnership with Meridian IT, a leading...
MATN : 0.2290 (+90.99%)
Mateon to Develop its OT-101, a Phase 3 Clinical Drug Candidate, Initially Against COVID-19
GlobeNewswire - Wed Mar 18, 7:00AM CDT
OT-101- a TGF-B2 inhibitor - has demonstrated potent antiviral activity against coronavirus
MATN : 0.2290 (+90.99%)
Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19
GlobeNewswire - Mon Mar 2, 6:50AM CST
Company has formed a new Division, led by Dr. Cyril Empig, to develop a multi-modal approach to treating the COVID-19 and future emergent zoonotic outbreaks
MATN : 0.2290 (+90.99%)
Mateon Therapeutics Team Publishes a New Peer-Reviewed Oncology Article on the Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients With Relapsed Acute Myeloid Leukemia
GlobeNewswire - Fri Dec 27, 7:30AM CST
Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD. PhD, the Chief Medical Officer for Mateon, Vuong Trieu, PhD, the...
MATN : 0.2290 (+90.99%)
Mateon Therapeutics Announces Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients with Relapsed Acute Myeloid Leukemia
GlobeNewswire - Mon Dec 23, 1:30PM CST
Mateon Therapeutics Inc. (OTCQB:MATN), dedicated to the development of innovative treatments for cancer, today announced that the multi-institutional OXI1222 study in people with previously treated relapsed...
MATN : 0.2290 (+90.99%)
EdgePoint announces collaboration with iBio CDMO to implement AI/Blockchain driven TrustPoint Vision Technology in its Texas cGMP facility
GlobeNewswire - Mon Dec 23, 8:30AM CST
TrustPoint has the potential to improve documentation processes by automating data documentation and verification leading to improved data integrity and reduced operating expenses
VSTCQ : 0.0001 (-90.00%) MATN : 0.2290 (+90.99%)
iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing
GlobeNewswire - Mon Dec 23, 7:30AM CST
iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint's proprietary artificial...
IBIO : 1.0550 (-4.95%) MATN : 0.2290 (+90.99%)
Steven King Named as Prospective CEO of EdgePoint AI
GlobeNewswire - Wed Dec 11, 7:30AM CST
Brings over 20 years of experience in drug development and pharmaceutical manufacturing, as well as Nasdaq listed public company experience
MATN : 0.2290 (+90.99%)
